Stocks to Watch: Horizon Pharma Inc (NASDAQ:HZNP), Avanir Pharmaceuticals (NASDAQ:AVNR), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), Supernus Pharmaceuticals (NASDAQ:SUPN)

Specialist pharmaceutical company Horizon Pharma Inc (NASDAQ:HZNP) revealed on Thursday the receipt of Notice of Allowance for US Patent Application 13/713,528 entitled “Delayed-Release Tablet with Defined Core Geometry” that covers its US approved product RAYOS. Horizon Pharma Inc (NASDAQ:HZNP) stock performance was -7.89% in last session and finished the day at $12.02. Traded volume was 3.88million shares in the last session and the average volume of the stock remained 2.63million shares. Horizon Pharma Inc (NASDAQ:HZNP) insider ownership is 0.60%.

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) is +0.0004 at $3.29, with 703,841 shares traded. As reported by Zacks, the current mean recommendation for AVNR is in the “buy range”. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) dropped -9.37 percent to $ 3.29 Friday on volume of 2.78million shares. The intra-day range of the stock was $3.28 to $3.69. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) has a market capitalization of $501.05million.

Pharmaceutical company Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) revealed on Tuesday the completion of its public offering at an offering price of USD2.21 per share. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)’s stock on Apr 11, 2014 reported a decrease of -7.21% to the closing price of $2.06. Its fifty two weeks range is $0.46-$3.65. The total market capitalization recorded $134.87million. The overall volume in the last trading session was million shares. In its share capital, CPRX has 65.49million outstanding shares.

Investors considering a purchase of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares, but tentative about paying the going market price of $9.29/share, might benefit from considering selling puts among the alternative strategies at their disposal. On Friday, shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) dropped -6.38% to close the day at $7.93. Company return on investment (ROI) is -105.30% and its monthly performance is recorded as -18.75%. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) quarterly revenue growth is -5.37%.